Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adagene

Shares of Adagene Inc. ADAG, +1.10% jumped 11.2% in premarket trading on Wednesday after it announced a licensing and commercialization deal with Sanofi SNY, -2.65% that is worth up to $2.5 billion. U.S.-listed shares of Sanofi were down 1.5%.

Sanofi to pay up to $2.5 billion in deal with Adagene

GlaxoSmithKline

GlaxoSmithKline PLC (LSE:GSK) and Sanofi SA said they plan to submit data from their booster and Phase III trials as a basis for their regulatory applications for a COVID-19 vaccine. The companies are in talks with regulatory authorities, including the US Food & Drug Administration and the European Medicines Agency.

GlaxoSmithKline and Sanofi plan to submit data from COVID-19 booster and Phase III trials for approval

Sanofi SA SNY, -0.80% and GlaxoSmithKline PLC GSK, -0.81% said Wednesday that their jointly-developed coronavirus vaccine has shown positive results in final-stage clinical trials and that they intend to seek regulatory approval for the shot.

Dow Jones Newswires: Sanofi, GSK to seek approval for Covid-19 vaccine after positive trial results

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine

Sanofi's Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors

Let's see if Sanofi (SNY) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Consider Sanofi (SNY) Stock Now?

Regeneron Pharmaceuticals

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (dupilumab) in chronic spontaneous urticaria (CSU). The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE: NVS) / Roche Holdings AG's (OTC: RHHBY) Xolair (omalizumab).

Sanofi-Regeneron's Dupixent Falls Short In Chronic Spontaneous Urticaria Trial

AbbVie

Amgen

Bristol-Myers

Vertex Pharmaceuticals

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

The FDA has accepted for Priority Review the supplemental marketing application for Dupixent (dupilumab) for children aged six months to 5 years with moderate-to-severe atopic dermatitis. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Sanofi - Regeneron's Dupixent Under FDA Priority Review For Children Under 5 Years With Atopic Dermatitis

The FDA approves Sanofi's (SNY) Enjaymo for the treatment of hemolysis in adult patients with cold agglutinin disease. Enjaymo is the first therapy to be approved for this indication.

Sanofi's (SNY) Enjaymo Gets FDA Nod For Rare Blood Disorder

R&D not priced in. Continued improvement of margins.

Sanofi: Our Next Value Pick

Sanofi (SNY) CEO Paul Hudson on Q4 2021 Results - Earnings Call Transcript

Sanofi (SNY) beats fourth-quarter estimates for earnings but misses the same for sales. Dupixent drives sales growth, offsetting lower vaccine sales.

Sanofi (SNY) Q4 Earnings Beat, Vaccines Hurt Sales Growth

Sanofi SA's SNY Q4 FY21 sales grew 4.1% to €9.99 billion, +6.5% (+4.1% on constant exchange rates). Get the Inside Access Traders Are Using to Profit More and Win Bigger.

Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars

French drugmaker Sanofi said it would aim to further increase its earnings per share (EPS) this year as it reported rising fourth-quarter results on Friday.

France's Sanofi eyes rising earnings in 2022 after Q4 earnings increase

Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity

Press Release: Sanofi unveils new corporate brand and logo – unites the company under one purpose and a single identity

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending expanding the use of Dupixent (dupilumab). [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

CHMP Backs Sanofi-Regeneron's Dupixent For Asthma Patients Aged 6 - 11 Years With Type 2 Inflammation

Regeneron Pharmaceuticals Inc  REGN and its partner Sanofi SA SNY have voluntarily withdrawn their application with the FDA for the expanded use of Libtayo in patients with advanced cervical cancer. [ALERT[ Matt Maley just released his latest pick with an upside of over 100% in 2 years.

Regeneron, Sanofi Withdraw FDA Application For Libtayo's Expanded Use

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.57% were down 0.1% in premarket trading on Friday after the company and Sanofi SNY, +3.00% said they will no longer seek Food and Drug Administration approval for Libtaya as a second-line treatment for cervical cancer. The therapy is currently approved to treat two forms of skin cancer and a type of lung cancer.

Regeneron, Sanofi withdraw application for Libtaya as a cervical cancer treatment in the U.S.

Sanofi's (SNY) PRIME is the second successful study on Dupixent for the prurigo nodularis indication.

Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal (Revised)

ABB Ltd.

Ashtead Group PLC

ASML Hld

Experian PLC

Nestle SA

Novo Nordisk

Roche Holding AG

Sage Group PLC/The

Unilever

A recent pullback in the global equities market has opened the door for investors to buy some of the top dividend-paying European stocks at a discount.

The 10 Best European Stocks for 2022 and Beyond

Sanofi (SNY) 2nd Dupixent Prurigo Nodularis Study Meets Goal

Regeneron (REGN) sBLA seeking label expansion of Libtayo in combination with chemotherapy as first-line treatment in advanced lung cancer accepted by the FDA.

Regeneron (REGN)/Sanofi's Libtayo sBLA Accepted by the FDA

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced data from the second Phase 3 trial of Dupixent (dupilumab) in adults with uncontrolled prurigo nodularis, a chronic type 2 inflammatory skin disease.  The trial met its primary and key secondary endpoints, showing it significantly reduced itch and skin lesions compared to placebo at 24 weeks.

Second Dupixent Phase 3 Trial Confirms Significant Improvements In Inflammatory Skin Disease

ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease ABL301 uses ABL's Grabody-B platform technology to effectively cross the blood-brain barrier ABL to receive $75M upfront and up to $985M in potential milestone payments for exclusive global license to ABL301 SEONGNAM, South Korea, Jan. 11, 2022 /PRNewswire/ -- ABL Bio, Inc. (KOSDAQ: 298380), a clinical-stage biotech developing bispecific antibody technology for immuno-oncology and neurodegenerative diseases, today announced an exclusive collaboration and worldwide license agreement with SANOFI to develop and commercialize ABL301, a pre-clinical stage bispecific antibody targeting alpha-synuclein and IGF1R to treat Parkinson's disease and other potential indications with enhanced blood-brain barrier (BBB) penetration. Under the terms of the agreement, ABL will receive $75 million in upfront payments.

News for Sanofi Stock (SNY)